Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. An industry perspective on health economics studies.
Anderson
K M
KM
Centocor, Inc., Malvern, PA 19355, USA.
Bala
M V
MV
Weisman
H F
HF
D000077284:Abciximab; D000789:Angina, Unstable / Q000188:drug therapy* / Q000191:economics*; D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003328:Coronary Thrombosis / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab